Erin Mistry
Corporate Officer/Principal en CORMEDIX INC. .
Fortuna: 55 167 $ al 31/03/2024
Perfil
Erin Mistry is currently the Chief Commercial Officer & Senior Vice President at CorMedix, Inc. (since 2023).
Prior to this, Mr. Mistry worked as the Vice President - Market Access at Intarcia Therapeutics, Inc.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CORMEDIX INC.
0.02% | 07/03/2024 | 13 011 ( 0.02% ) | 55 167 $ | 31/03/2024 |
Cargos activos de Erin Mistry
| Empresas | Cargo | Inicio |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | 01/01/2020 |
Antiguos cargos conocidos de Erin Mistry.
| Empresas | Cargo | Fin |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Erin Mistry
